GURUFOCUS.COM » STOCK LIST » USA » NAS » Eiger BioPharmaceuticals Inc (NAS:EIGR) » Definitions » Financial Strength
Switch to:

Eiger BioPharmaceuticals Financial Strength

: 5 (As of Jun. 2022)
View and export this data going back to 2014. Start your Free Trial

Eiger BioPharmaceuticals has the Financial Strength Rank of 5.

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.

Eiger BioPharmaceuticals did not have earnings to cover the interest expense. Eiger BioPharmaceuticals's debt to revenue ratio for the quarter that ended in Jun. 2022 was 2.40. As of today, Eiger BioPharmaceuticals's Altman Z-Score is -0.05.


Competitive Comparison

For the Biotechnology subindustry, Eiger BioPharmaceuticals's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Eiger BioPharmaceuticals Financial Strength Distribution

For the Biotechnology industry and Healthcare sector, Eiger BioPharmaceuticals's Financial Strength distribution charts can be found below:

* The bar in red indicates where Eiger BioPharmaceuticals's Financial Strength falls into.



Eiger BioPharmaceuticals Financial Strength Calculation

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

Eiger BioPharmaceuticals's Interest Expense for the months ended in Jun. 2022 was $-0.93 Mil. Its Operating Income for the months ended in Jun. 2022 was $-20.08 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2022 was $38.92 Mil.

Eiger BioPharmaceuticals's Interest Coverage for the quarter that ended in Jun. 2022 is

Eiger BioPharmaceuticals did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

2. Debt to revenue ratio. The lower, the better.

Eiger BioPharmaceuticals's Debt to Revenue Ratio for the quarter that ended in Jun. 2022 is

Debt to Revenue Ratio=Total Debt (Q: Jun. 2022 ) / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0.436 + 38.919) / 16.364
=2.40

3. Altman Z-Score.

Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

The zones of discrimination were as such:

When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.

Eiger BioPharmaceuticals has a Z-score of -0.05, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

Warning Sign:

Altman Z-score of -0.05 is in distress zone. This implies bankruptcy possibility in the next two years.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Eiger BioPharmaceuticals  (NAS:EIGR) Financial Strength Explanation

The maximum rank is 10. Companies with rank 7 or higher will be unlikely to fall into distressed situations. Companies with rank of 3 or less are likely in financial distress.

Eiger BioPharmaceuticals has the Financial Strength Rank of 5.


Eiger BioPharmaceuticals Financial Strength Related Terms

Thank you for viewing the detailed overview of Eiger BioPharmaceuticals's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.


Eiger BioPharmaceuticals Business Description

Eiger BioPharmaceuticals logo
Traded in Other Exchanges
Address
2155 Park Boulevard, Palo Alto, CA, USA, 94306
Eiger BioPharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of drugs for serious, rare, and ultra-rare diseases with high unmet medical needs and no approved therapies. Its program lonafarnib, a prenylation inhibitor, boosted with ritonavir, for the treatment of Hepatitis Delta Virus (HDV) infection, is in Phase 3 clinical development. Its product candidate pipeline includes Lonafarnib (LNF) in HDV, Peginterferon Lambda (lambda) in HDV, LNF in Progeria, and Progeroid Laminopathies (PL), Avexitide in Post-Bariatric Hypoglycemia (PBH), and Avexitide in Congenital Hyperinsulinism (CHI), all advancing toward Phase 3.
Executives
Apelian David director C/O ACHILLION PHARMACEUTICALS, INC 300 GEORGE STREET NEW HAVEN CT 06511
Atkisson Erik officer: GC & Chief Compliance Officer C/O EIGER BIOPHARMACEUTICALS, INC. 2155 PARK BLVD. PALO ALTO CA 94306
Sablich Kim director C/O MYOVANT SCIENCES INC. 2000 SIERRA POINT PARKWAY BRISBANE CA 94005
Mayer Eldon C. Iii officer: Ex VP & Chief Commerc. Officer RIGEL PHARMACEUTICALS, INC. 1180 VETERANS BLVD. SOUTH SAN FRANCISCO CA 94080
Ryali Sriram officer: Chief Financial Officer C/O EIGER BIOPHARMACEUTICALS, INC. 2155 PARK BLVD. PALO ALTO CA 94306
Cory David A director, officer: President and CEO 350 CAMBRIDGE AVENUE, SUITE 350 PALO ALTO CA 94306
Loh Evan director 75 KNEELAND STREET BOSTON MA 02111
Murray Christine director C/O ACHAOGEN, INC. 7000 SHORELINE COURT, SUITE 371 SOUTH SAN FRANCISCO CA 94080
Dietz Thomas John director C/O TRANSCEPT PHARMACEUTICAL, INC. 1003 W. CUTTING BLVD, STE 110 PT. RICHMOND CA 94804
Glenn Jeffrey S director 350 CAMBRIDGE AVENUE, SUITE 350 PALO ALTO CA 94306
Sachdev Amit director C/O VERTEX PHARMACEUTICALS INCORPORATED 130 WAVERLY STREET CAMBRIDGE MA 02139
Patton Stephana Eilene officer: See Remarks 1010 ATLANTIC AVENUE ALAMEDA CA 94501
Ra Capital Healthcare Fund Lp 10 percent owner 200 BERKELEY STREET 18TH FLOOR BOSTON MA 02116
Ra Capital Management, L.p. 10 percent owner 200 BERKELEY STREET, 18TH FLOOR BOSTON MA 02116
Kolchinsky Peter 10 percent owner 200 BERKELEY STREET 18TH FLOOR BOSTON MA 02116

Eiger BioPharmaceuticals Headlines

From GuruFocus

Other Sources

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)